Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.59 |
| ▸ | MAPT | P10636 | 6/20 | 0.59 |
| ▸ | GFER | P55789 | 2/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | RAD52 | P43351 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.42 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1726121 | 0.98 | ALDH1A1 (0.57) | ALDH1A1MAPTGFERTDP1LMNA | |
| SCHEMBL3027517 | 0.86 | MAPT (0.57) | ALDH1A1MAPTGFERTDP1LMNA | |
| SCHEMBL17265648 | 0.85 | ALDH1A1 (0.77) | ALDH1A1MAPTGFERTDP1LMNA | |
| SCHEMBL159281 | 0.83 | MAPT (0.68) | ALDH1A1MAPTGFERTDP1LMNA | |
| SCHEMBL16391106 | 0.82 | MAPT (0.54) | ALDH1A1MAPTGFERTDP1LMNA | |
| SCHEMBL1641810 | 0.81 | MAPT (0.52) | ALDH1A1MAPTGFERTDP1LMNA | |
| SCHEMBL29520597 | 0.80 | ALDH1A1 (0.66) | ALDH1A1MAPTGFERTDP1LMNA | |
| SCHEMBL159044 | 0.80 | ALDH1A1 (0.66) | ALDH1A1MAPTGFERTDP1LMNA | |
| SCHEMBL157877 | 0.79 | MAPT (0.56) | ALDH1A1MAPTGFERTDP1LMNA | |
| SCHEMBL1127846 | 0.79 | MAPT (0.56) | ALDH1A1MAPTGFERTDP1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117486865-A | Pyrimidine derivatives as kinase inhibitors | 艾森医药公司 | 2024-02-02 | — | — | CN | disclosed |
| CN-112592334-B | Pyrimidine derivatives as kinase inhibitors | 艾森医药公司 | 2023-10-27 | — | — | CN | disclosed |
| US-10562918-B2 | Heterocyclic compounds and uses thereof | ACEA Therapeutics, Inc. (US) | 2020-02-18 | — | — | US | disclosed |
| US-10562918-B2 | Heterocyclic compounds and uses thereof | ACEA Therapeutics, Inc. (US) | 2020-02-18 | — | — | US | disclosed |
| EP-3019496-B1 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | ACEA THERAPEUTICS INC (US) | 2019-09-11 | — | — | EP | disclosed |
| EP-3019496-B1 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | ACEA THERAPEUTICS INC (US) | 2019-09-11 | — | — | EP | disclosed |
| US-20180251475-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ACEA BIOSCIENCES INC. | 2018-09-06 | — | — | US | disclosed |
| US-9920074-B2 | Heterocyclic compounds and uses thereof | ACEA BIOSCIENCES INC. (US) | 2018-03-20 | — | — | US | disclosed |
| US-9920074-B2 | Heterocyclic compounds and uses thereof | ACEA BIOSCIENCES INC. (US) | 2018-03-20 | — | — | US | disclosed |
| US-9920074-B2 | Heterocyclic compounds and uses thereof | ACEA BIOSCIENCES INC. (US) | 2018-03-20 | — | — | US | disclosed |
| US-20110319392-A1 | Thiazole Sulfonamide And Oxazole Sulfonamide Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2011-12-29 | — | — | US | disclosed |
| US-20110319392-A1 | Thiazole Sulfonamide And Oxazole Sulfonamide Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2011-12-29 | — | — | US | disclosed |
| US-20110190280-A1 | Thiazole And Oxazole Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2011-08-04 | — | — | US | disclosed |
| US-20110190280-A1 | Thiazole And Oxazole Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2011-08-04 | — | — | US | disclosed |
| US-20110190280-A1 | Thiazole And Oxazole Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2011-08-04 | — | — | US | disclosed |
| WO-2010104899-A1 | THIAZOLE SULFONAMIDE AND OXAZOLE SULFONAMIDE KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2010-09-16 | — | — | WO | disclosed |
| WO-2010104899-A1 | THIAZOLE SULFONAMIDE AND OXAZOLE SULFONAMIDE KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2010-09-16 | — | — | WO | disclosed |
| EP-2197876-A1 | THIAZOLE AND OXAZOLE KINASE INHIBITORS | Glaxosmithkline LLC (US) | 2010-06-23 | — | — | EP | disclosed |
| WO-2009032667-A1 | THIAZOLE AND OXAZOLE KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-03-12 | — | — | WO | disclosed |
| WO-2009032667-A1 | THIAZOLE AND OXAZOLE KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190280-A1 | Thiazole And Oxazole Kinase Inhibitors | PDXK, MAP3K1, MAP4K2 | ALDH1A1 3014/4885MAPT 1402/4885GFER 4646/4885 |
| US-10562918-B2 | Heterocyclic compounds and uses thereof | BMX, BLK, BTK | ALDH1A1 4165/4885MAPT 2803/4885GFER 2806/4885 |
| US-20110319392-A1 | Thiazole Sulfonamide And Oxazole Sulfonamide Kinase Inhibitors | STK24, MAP3K5, MAP3K2 | ALDH1A1 2613/4885MAPT 2542/4885GFER 2374/4885 |
| US-20180251475-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | BMX, BLK, BTK | ALDH1A1 4165/4885MAPT 2803/4885GFER 2806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.